8. The emergence of health economics
• The rise and rise of health with economic
development
• The recognition of unsustainability first with the
exponential increase in drug costs in the 1980s
– Australia first country to mandate cost-
effectiveness for reimbursement
– More recently - all technologies assessed for cost-
effectiveness through MSAC prior to listing on
Medicare.
10. Measuring cost-effectiveness
Methodology is prescriptive and accepted
globally
Provides comparative analysis of alternative
courses of action in health services, in terms of
both their costs and consequences
Most commonly reported as cost per LYG or
cost per QALY
Rarely means saving money – it usually refers to
an acceptable investment for the expected return
10
12. What is a good buy?
• Achieving health gains and concurrently reducing
cost is ‘cost-effective’ (but uncommon)
• Implicit threshold determine what is ‘cost-effective’
eg $50,000 per QALY gained
• Rule of thumb for global considerations given as
3XGDP per capita per DALY
• Value depends on society’s willingness to pay
where the decision rule is determined by i) budget
or ii) price per effective unit
12
13. The cost effectiveness threshold and value
• All QALYs are not created equal – society is prepared
to pay more for some life years than others
• Implicit utilitarian principle of maximising years of life
seems in conflict with this (Equity-efficiency trade-off)
• Two broad objectives of a health system – to maximise
the health of the population and to reduce inequalities.
• Can ‘value’ take account of both by incorporating more
than a quality year of life – eg ethical principle of acting
when there is the opportunity to save a life??
13
14. The ‘rule of rescue’
• Term coined by Jonsen (1986) to describe the
perceived duty of protecting a life even when the
resources may be used more efficiently
• Example of Oregon’s priority list for Medicaid based
on quality of expected outcomes and cost (cost-
effectiveness). The list was revised before it
reached the legislature because of obersight with
regard to life-saving treatments
• Value judgement will always be a factor in priority
setting
14
15. Criteria for prioritising interventions
o ‘Rule of rescue’
o Priority for more severe disease
o Priority for children and young adults over the elderly
o Priority for a greater spread of benefit rather that a
large benefit for a few
o Priority where there is a greater potential for
improvement
16. The case of ICU
• In the last 30 years – from life-threatening illnesses
for individuals expected to make a full recovery
(primarily infections and trauma) to a place for the
seriously ill, often with complex diseases, often
aged and often for end-of-life care
• This is particularly well documented in the U.S.
where one in three Medicare beneficiaries spends
time in ICU during their last month of life
• In an age where we can always do more, does ICU
present an exception?
16
19. Cost-effectiveness in ICU
• Reduction in waste
• Reduction in errors
• Preventive care
• ? Reductions in LoS? (mixed results)
• ? Role substitution (some evidence of reduced
efficiency)
• Advanced care directives
19
20. End of life care
• In the last month of life, 1 in 3
Medicare beneficiaries is admitted to
an ICU*
• Very little evidence-base for
outcomes*
• Should the cost of care influence
decisions?
Halpern NEJM 2015 373:21
21. Conclusion
oIn an era of an increasing need for evidence-
based policy, health interventions require objective
evaluation of their societal value, both from a
clinical and an economic perspective
oAre we currently achieving best value or should
we consider re-ordering priorities and changing our
approach to funding and service delivery?
oPressure on the health dollar combined with ever
increasing expectations of optimal health and
survival will require community discussion around
difficult prioritisation decisions
Health expenditure growth in 2013–14 was relatively slow according to most measures. Total expenditure on health was estimated at $154.6 billion in 2013–14, up by 3.1% on 2012–13 in real terms (after adjusting for inflation). This growth was higher than the 1.1% growth experienced in 2012–13 but 1.9 percentage points lower than the average annual growth over the past decade (5.0%).
Growth was also relatively slow in expenditure per person. An estimated $6,639 was spent per person on health in 2013–14, which was $94 more in real terms than in the previous year. This growth of 1.4% was less than half the average annual growth over the decade (3.3%).
Despite this relatively slow growth in health spending, the proportion of the economy that health represented increased from 9.7% of gross domestic product (GDP) in 2012–13 to 9.8% in 2013–14. This was a result of relatively low growth in GDP.
When compared to taxation revenue, government health spending represented the same proportion of taxation revenue (24.7%) as the previous year.
The institute aims to compare effectiveness not cost-effectiveness and is legally prohibited from comparing the value of cost per QALY or any other ratio against given thresholds in making recommendations
Very contentious and hotly debated within the US and in stark contrast to NICE and Australian bopied who make recommendations usually based on cost per QALY
But suffice to say that the US already spends around twice the proportion of GDP compared with other industrialised nations and their outcomes tend to be poorer
illustration
Ways of responding to increasing demand on expenditure
What we’ll be talking about today is the methodolgy for assessing the value for money - ie cost-effectiveness of interventions in health.